Intensive therapy followed by hematopoietic progenitor TNF-␣ (Tumor necrosis factor-alpha) is involved in administration has improved the prognosis of many dismany immunological and inflammatory processes, and eases in the last 30 years. However, this procedure is commight be expected to play an important role in the plicated by secondary events which may endanger the development of BMT-related complications. Triple therpatient's life in 23-35% of cases. 1 Conditioning-related apy (pentoxifylline, ciprofloxacin and prednisone) with toxicity, graft rejection, graft-versus-host disease and postknown anti-TNF activity was tested in 37 patients undergoing a hematopoietic progenitor transplant transplant immunodeficient status are the most frequent (HPT). A control group of 16 patients with similar complications after hematopoietic progenitor transplancharacteristics was selected among consecutive patients tation (HPT). receiving a HTP in a neighboring center who did not Basal disease, the source of hematopoietic progenitors receive anti-TNF prophylaxis. Major transplant-related and conditioning therapy used also influence patients' outcomplications were registered (VOD, acute GVHD, come. infectious episodes, renal failure and mucositis) and sur-TNF-␣ and other inflammatory cytokines have directly vival status. TNF plasma concentrations were deterbeen involved in tissue damage after HPT. 2 High TNF-␣ mined by ELISA, and pentoxifylline plasma concenlevels have been detected in patients with infectious epitrations were determined by HPLC. Among patients sodes, graft-versus-host disease (GVHD) and hepatic venotreated with pentoxifylline (PTX), ciprofloxacin and occlusive disease (VOD). 3, 4 As TNF-␣ is thought to be steroids, no difference in the mean survival time was responsible for the initiation and perpetuation of tissue observed compared with the control group. The incidamage, strategies such as anti-TNF antibody adminisdence of procedure-related death up to day +35 was tration 5 or inhibition of TNF synthesis have been assessed 11% in the study group and 6% in the control group.
Intensive therapy followed by hematopoietic progenitor TNF-␣ (Tumor necrosis factor-alpha) is involved in administration has improved the prognosis of many dismany immunological and inflammatory processes, and eases in the last 30 years. However, this procedure is commight be expected to play an important role in the plicated by secondary events which may endanger the development of BMT-related complications. Triple therpatient's life in 23-35% of cases. 1 Conditioning-related apy (pentoxifylline, ciprofloxacin and prednisone) with toxicity, graft rejection, graft-versus-host disease and postknown anti-TNF activity was tested in 37 patients undergoing a hematopoietic progenitor transplant transplant immunodeficient status are the most frequent (HPT). A control group of 16 patients with similar complications after hematopoietic progenitor transplancharacteristics was selected among consecutive patients tation (HPT).
receiving a HTP in a neighboring center who did not
Basal disease, the source of hematopoietic progenitors receive anti-TNF prophylaxis. Major transplant-related and conditioning therapy used also influence patients' outcomplications were registered (VOD, acute GVHD, come. infectious episodes, renal failure and mucositis) and sur-TNF-␣ and other inflammatory cytokines have directly vival status. TNF plasma concentrations were deterbeen involved in tissue damage after HPT. 2 High TNF-␣ mined by ELISA, and pentoxifylline plasma concenlevels have been detected in patients with infectious epitrations were determined by HPLC. Among patients sodes, graft-versus-host disease (GVHD) and hepatic venotreated with pentoxifylline (PTX), ciprofloxacin and occlusive disease (VOD). 3, 4 As TNF-␣ is thought to be steroids, no difference in the mean survival time was responsible for the initiation and perpetuation of tissue observed compared with the control group. The incidamage, strategies such as anti-TNF antibody adminisdence of procedure-related death up to day +35 was tration 5 or inhibition of TNF synthesis have been assessed 11% in the study group and 6% in the control group.
in order to decrease transplant-related complications. In spite of a tendency to a lower incidence of mucositis Pentoxifylline (PTX) is a xanthine with a strong inhibithere was a higher incidence of infections (positive blood tory effect on TNF synthesis in vitro, 6 which may also procultures) in the study group (49%) than in the control tect experimental animals from renal dysfunction induced group (16.7%) (P = 0.16). This difference achieved statby cyclosporin A or amphotericin B. 7, 8 istical significance in patients receiving an allogeneic Bianco et al 9 showed a decreased incidence of VOD, HPT (P = 0.05). It is likely that the use of steroids in the GVHD, mucositis, renal failure and fever in patients early period after transplant increases infectious epiundergoing BMT treated with PTX orally. Later reports sodes and makes control of GVHD difficult. The com-
have not proven such a benefit. 10, 11 bined administration of steroids with pentoxifylline and Steroids and ciprofloxacin have a well-known inhibitory ciprofloxacin has not proved beneficial in preventing effect on TNF secretion 12, 13 and may increase the anti-TNF mucositis, renal failure, VOD or GVHD, or in improveffect of PTX in vitro.
Patients and methods

Blood sample collection
Blood samples were collected 2 h after first PTX adminisPatient selection tration on days −7, −1, +1, +7, +14, +21, +28 and +35. They were collected in tubes containing EDTA and sodium From September 1993 to October 1994, consecutive citrate. Aprotinin (Trasylol; Bayer, Leverkußen, Germany) patients undergoing bone marrow or a PBSC transplanhad been previously added to EDTA tubes at a concentation in our center received anti-TNF prophylaxis with tration of 150 kalicrein inhibitor units/ml in order to avoid pentoxifylline, prednisone and ciprofloxacin. A control spontaneous activation of monocytes. Samples were placed group of patients of similar characteristics undergoing HPT on ice and centrifuged within 2 h after blood collection as in a neighboring centre (Hospital de Santa Creu i Sant Pau, described by Bianco et al. 9 The plasma samples were transBarcelona) during the same time period was studied.
ferred to microfuge tubes and frozen to −70°C until assay. Exclusions from this study were those which generally contraindicate transplantation.
Determination of TNF-␣ plasma levels TNF-␣ plasma levels were determined by a double antiTransplantation procedure and supportive care body sandwich immunoassay (ELISA; Immunotech International, Montpellier, France). This assay was carried out Similar protocols were followed in both hospitals for according to the manufacturer's instructions. TNF-␣ conpatient conditioning, for GVHD prophylaxis and treatment centrations in real plasma samples were calculated using and for supportive care after transplantation. Maximal temcalibration curves obtained with cytokine standards. perature and signs of infection, body weight, fluid balance, vomiting (WHO scale), mucositis according to Bearman et al, 16 episodes of diarrhea and cutaneous inspection were Determination of pentoxifylline plasma levels registered daily.
The concentration of pentoxifylline in plasma was deterProphylactic antibiotics used were trimethoprim/ mined by HPLC with a method based in the previously sulfamethoxazole in the control group and ciprofloxacin in described by Garnier-Moireaux et al.
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the study group. Patients were started on broad spectrum antibiotics (ceftacidime plus vancomycin, or imipenem) when temperatures exceeded 38°C and after blood cultures Statistical analysis had been drawn. Amphotericin B was added for persistent The 2 test or the Fisher exact test were used for statistical fever or documented fungal infection. In the study group, evaluation of qualitative variables. Differences were conciprofloxacin was continued when empirical antibiotic sidered statistically significant when P Ͻ 0.05. For comtreatment was introduced.
parison of median values (differences between the control Packed red cells were given when the hemoglobin level and study groups) the Mann-Whitney U-test was used. The was less than 8.0 g/dl and platelet transfusions were adminWilcoxon signed rank test was also used whenever variistered when the platelet count was below 20 × 10 9 /l. ables did not follow a normal distribution. Correlations between numerical variables were assessed using Spearman rank test. The mean survival time was estimated by the
Definition of major transplant-related complications
Kaplan-Meier method. A diagnosis of hepatic VOD required the presence of hyperbilirubinemia (Ͼ3.0 mg/dl), weight gain Ͼ2.5% of Results baseline weight and right upper quadrant pain with or without hepatomegaly.
17 GVHD was evaluated following TNF plasma levels were determined in 37 patients who the Seattle criteria.
18 Severity of mucositis was scored in received triple anti-TNF prophylaxis with PTX, prednisone accordance with previous published criteria 16 and the numand ciprofloxacin and who were planned to receive an allober of days of continuous morphine sulphate administration geneic BMT (n = 21), autologous BMT (n = 10) or periphand parenteral nutrition were used as objective parameters eral blood autologous stem cell transplantation (n = 6). TNF for severity of mucositis.
plasma levels were also analyzed in 16 patients undergoing hematopoietic progenitor transplantation who did not receive treatment with PTX, ciprofloxacin or steroids Anti-TNF prophylaxis (control group). One patient in the study group did not receive prednisone because he suffered from diabetes melPatients in the study group received pentoxifylline 400 mg/6 h p.o. from day −7 to day +35 after transplant, litus and had developed ketosis before the transplant. The dose of prednisone administered to patients in the study ciprofloxacin 500 mg/12 h p.o. or 200 mg/12 h i.v. from day −1 to day +35 and prednisone orally or intravenously group was changed during the study because of a strong concern over infectious complications. Twelve patients out from day −7 to day +35. Prednisone was slowly tapered after day +35 and finally stopped. Pentoxifylline was interof 21 undergoing allogeneic BMT received a prednisone dose of 2 mg/kg/day and nine patients 1 mg/kg/day. Five rupted when the patient could not swallow it or refused to take it.
patients out of 15 undergoing an autologous transplantation received prednisone 1 mg/kg/day and 10 patients received who did not have a diagnosis of acute or chronic myeloid leukemia) received a myeloid growth factor (G-or GMprednisone 0.5 mg/kg/day. No patient from the control group received prednisone early after transplant. Steroids CSF) (P Ͻ 0.000). were only started when GVHD developed. Both groups of patients were comparable in age, sex and source of hemato-TNF and PTX plasma levels poietic progenitors (Table 1 ). In the study group, 38% of In Figure 1 , the average TNF-␣ levels and their 95% conthe patients had a diagnosis of CML, while none was fidence intervals are shown. For each study day no differobserved in the control group (Table 2) . Disease status of ences in TNF-␣ plasma levels were seen between the study the patients at transplantation was, however, similar in and control groups. both groups.
PTX concentrations were determined only in patients Patients receiving an allogeneic BMT at high risk of from the study group (Table 3 ). The average levels of PTX developing GVHD received a partially T cell-depleted bone in patients were good. Levels were not identifiable in seven marrow (11 patients out of 21 in the study group and two patients who did not tolerate oral PTX during the period patients out of four in the control group). GVHD prophyof maximal mucositis, which was associated with nausea laxis consisted of standard methotrexate on day +1
and vomiting (these patients were kept on steroid and cipro-(15 mg/m 2 ), and on days +3, +6, +11 (10 mg/m 2 ), and of floxacin treatment). There was no difference in TNF concyclosporin A (3 mg/kg/day) from day −1 in all patients.
centration among the different days tested in the group of Growth factors were routinely administered in the study patients that did and did not take PTX according to the group (36 patients received G-CSF and one patient received study design (P Ͼ 0.1). GM-CSF). Only 51% of patients in the control group (those PTX and TNF plasma levels had a low correlation coefficient, so TNF plasma levels were not affected by PTX Table 2 Basal diagnosis and disease status previous to transplant of treatment at the dose administered in this study. 80% for the study group (P Ͻ 0.020) (Figure 2 
Infectious complications
Ͼ1st CR or Ͼ1st CP 21 (57) 9 (57)
As compared with the control group, the study group ALL = acute lymphoid leukemia; AML = acute myeloid leukemia;
showed a shorter period of neutropenia, lower number of CML = chronic myeloid leukemia; NHL = non-Hodgkin's lymphoma; days with fever and fewer days on antibiotics. None of HD = Hodgkin's disease; CR = complete remission; CP = chronic phase (for CML patients).
these differences reached statistical significance (Table 4) .
genes dentifricans, Escherichia coli and Xanthomona maltophilia. Among patients undergoing an autologous BMT there were no increase in incidence of bacteremia associated with triple therapy.
Among patients undergoing an allogeneic BMT, positive blood cultures were significantly more often detected in the study group (61.9%) than in the control group (16.7%) (P = 0.05). Patients undergoing allogeneic BMT received higher doses of prednisone (2-1 mg/kg/day), than patients undergoing autologous BMT (1-0.5 mg/kg/day).
Mucositis grade 3 and 4 were more likely in the control group (56.3%) than in the study group (32.4%), although differences did not achieve statistical significance. Patients with more severe mucositis required parenteral nutrition (TPN) for a longer period of time (P = 0.005).
Need for TPN was positively related to the first day after transplant when the neutrophil count was higher than 500 × 10 6 /l (r = 0.3792, P = 0.005). There was a negative relationship between duration of TPN and the dose of prednisone administered (r = −0.2802, P = 0.042).
Patients in triple therapy group required more days of TPN (18.7 ± 1.5 days) as compared to the control group (29.5 ± 2.9 days) (P = 0.003) and they were less likely to need intravenous morphine (19.6 ± 3.4 days vs 32.5 ± 7.6 days, P = 0.15).
There was no difference in creatinine level between patients from the control group (25%) developed the three criteria of VOD (hepatomegaly and/or pain in the right upper quadrant, hydric retention and hyperbilirubinemia) (P = 0.19). There was no difference in GVHD incidence and severity between groups until day +35 after transplant (15% vs 6%, P = 0.32). Some patients developed GVHD when prednisone was tapered after day +35, and when it appeared, GVHD was more difficult to treat, even with high dose steroids and antilymphocyte serum. The overall incidence of acute GVHD III-IV beyond day +35 was 28% in the study group and 14% in the control group.
Discussion
In this study, we evaluated the efficacy of treatment with secretion. The secondary effects and outcome of 37 patients undergoing HPT with PTX, ciprofloxacin and prednisone were compared with the events and outcome in a group of Positive blood cultures were documented in 49% of patients in the study group vs 25% in the control group 16 patients in which these drugs were not included in the standard treatment. (P = 0.16). Documented bacteremias in the study group were due to: coagulase-negative Staphylococcus, viridans
No statistically significant differences in TNF levels were found between the study group and the control group.
Streptococcus, faecalis Enterococcus, agalactie Streptococcus, pneumoniae Streptococcus and sanguis Streptococcus.
Oral treatment with 400 mg of pentoxifylline every 6 h may not be enough to reach the necessary PTX concentration to Two cases in the study group had septic shock and ADRS related to viridans Streptococcus infection. In the control inhibit TNF secretion in vitro.
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The differences in plasma TNF levels reported in the group, documented bacteremias were due to: coagulasenegative Staphylococcus, faecalis Enterococcus, Alcaliliterature could be explained by the short plasma half-life patients undergoing allogeneic BMT who received methylprednisolone (1 mg/kg/day until day +22 and 0.5 mg/ kg/day until day +35). 28 In our study, two patients from the study group developed ADRS associated with viridans of this cytokine. The ELISA is a semiquantitative technique Streptococcus infection. Ciprofloxacin which was used in and may also detect immunoreactive cytokine that is not our study group as a TNF-inhibitor and selective intestinal biologically active.
decontamination has been described as a predisposing facPatient characteristics such as age, sex, hematopoietic tor for ADRS. Moreover, Elting et al 29 showed a good corprogenitor source or TBI as part of the conditioning therrelation between ADRS, viridans Streptococcus infection, apy, were similar in both groups. However, there was a quinolones, H2 antagonists and severe neutropenia. higher proportion of patients with CML in the study group Our observation of more mucositis in the control group, but evolution of disease was similar. Some authors suggest although statistically insignificant was in agreement with a worse prognosis for patients with CML, but this remains the findings of Bianco et al. 27 Suprisingly, we observed a controversial. A worse prognosis has also been attributed higher incidence of documented infections within the group to patients with more advanced disease. 10 that received prophylaxis. However, a lower infection rate Patients undergoing BMT who received the triple treatwas expected in the group that had preservation of the ment with PTX, ciprofloxacin and steroids had lower surmucosal barrier. We have to assume that the immunosupvival rates, which may be explained by the higher incidence pressive effect of prednisone was stronger than its protecof infectious complications and more frequent GVHD in tive effect on the mucosal barrier. this group, as compared to the control group.
GVHD incidence in patients undergoing allogeneic BMT Bianco et al 9, 20 showed that the administration of PTX varies between 20 and 80%. This depends on the degree of in patients undergoing BMT reduced the incidence of VOD, HLA disparity between donor and recipient, the age of the GVHD, mucositis, renal failure and fever. Bianco et al 21 recipient and GVHD prophylaxis used.
30, 31 The incidence related the benefits of PTX in their patients to the fact that of GVHD was similar in both groups until day +35. Predni-PTX was administered orally. However, subsequent reports sone administered as part of the anti-TNF prophylaxis, also have been unable to prove such a benefit from PTX adminhas an effect in preventing GVHD. In the study group, istration [22] [23] [24] even when administered orally. 10, 11, 25 GVHD appeared after tapering or stopping prednisone. In Steroids and ciprofloxacin have a well-known inhibitory these cases, GVHD was difficult to treat as it evolved to effect on TNF secretion 12, 13 and when administered alone grade III and IV, and was the cause of death in some or in combination, may increase the inhibitory effect of patients. PTX on TNF secretion. 14, 15, 26 Bianco et al 27 reported a benOur group does not use any more prednisone in the early eficial effect by using PTX, ciprofloxacin and steroids in a period after transplant because steroids facilitate infectious small group of patients undergoing a BMT.
In spite of the limited number of patients, statistically episodes and render the control of GVHD difficult. More- 
